Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L6KC
|
|||
| Former ID |
DIB013164
|
|||
| Drug Name |
BILR-355
|
|||
| Synonyms |
BILR-355-BS; 11-Ethyl-5-methyl-8-[2-(1-oxidoquinolin-4-yloxy)ethyl]-6,11-dihydro-5H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
Click to Show/Hide
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 2 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Inhibitor | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00294372) Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients. U.S. National Institutes of Health. | |||
| REF 2 | Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther. 2012 Feb;37(1):81-8. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.